Gem Aromatics reported a standalone profit for Q1 FY27 but a consolidated net loss. The loss is due to high depreciation from its new Dahej facility, which is still in its commercialization phase.
Gem Aromatics Q1 FY27 Results: Standalone Profit, Consolidated Loss Amid New Facility Commercialization
Gem Aromatics reported a standalone profit of Rs 7.3 crore for the quarter ended June 30, 2026, while its consolidated operations registered a net loss of Rs 7.9 crore. Reader Takeaway: Standalone profit a positive, but consolidated loss highlights new facility costs. ## What just happened Gem Aromatics announced its financial results for the first quarter of FY27. On a standalone basis, the company reported a revenue of Rs 83 crore and a Profit After Tax (PAT) of Rs 7.3 crore. However, consolidated financials showed a revenue of Rs 99 crore and a Net Loss of Rs 7.9 crore. The consolidated loss was significantly impacted by a depreciation charge of Rs 9.1 crore related to its new Dahej facility. ## Why this matters The results highlight a divergence between the company's core business performance and the impact of its new, high-capex expansion. While the standalone business is profitable, the consolidated figures reflect the initial costs associated with commercializing the Dahej facility under Krystal Ingredients Private Limited. This includes substantial depreciation and operating expenses before higher-margin revenues begin to flow in meaningfully. ## The backstory Gem Aromatics has invested approximately Rs 270 crore in its Dahej facility, with Rs 265 crore already incurred and capitalized. This facility is crucial for the company's strategy to diversify its product portfolio beyond its traditional clove business. ## What changes now The company is in the commercialization phase for new verticals like Safranal, Cooling Agents (Gemcool), and Phenol Derivatives. While Safranal and Cooling Agents have commenced production, significant revenue contributions are expected from Q3 FY27 onwards. Phenol Derivatives are slated for commercial production by Q3 FY27, with revenue contribution by Q4 FY27. Management expects Krystal products to constitute over 50% of revenue by FY28. ## Risks to watch Consolidated profitability will likely remain under pressure in the near term due to the depreciation and operating costs of the new facility. The core clove business faces supply chain risks, as evidenced by the recent disruption in Madagascar due to cyclones and floods. Future revenue growth is also dependent on successful customer approvals for new products. ## Peer comparison Information regarding specific peers' recent financial performance is not available in the filing. However, companies in the specialty chemicals and aroma ingredients sectors often face similar challenges with new plant commissioning, involving significant capital expenditure and a ramp-up period for revenue generation. ## Context metrics (time-bound) In Q1 FY27, consolidated revenue grew to Rs 99 crore from Rs 88 crore in Q1 FY26. The Dahej facility's capex stands at Rs 265 crore. The consolidated depreciation charge for the quarter was Rs 9.1 crore. ## What to track next Investors should monitor the revenue ramp-up from the new product verticals, particularly Safranal and Cooling Agents, in the upcoming quarters. The company's ability to manage its cost structure and achieve higher margins from the Dahej facility will be critical. Additionally, the impact of the Madagascar supply chain situation on the clove business needs to be watched.
